Expert Opinion for Use of Faecal Calprotectin in Diagnosis and Monitoring of Inflammatory Bowel Disease in Daily Clinical Practice

Overview

Journal United European Gastroenterol J

Publisher Wiley

Specialty Gastroenterology

Date 2018 Oct 6

PMID 30288273

Citations 19

Authors

Catherine Reenaers

Peter Bossuyt

Pieter Hindryckx

Hilde Vanpoucke

Anneline Cremer

Filip Baert

Affiliations

Soon will be listed here.

Abstract

Background: Despite many publications regarding the role of faecal calprotectin (FC) in inflammatory bowel disease (IBD), clear recommendations for its use in clinical practice are currently lacking in the literature.

Aim: The aim of this article is to provide practical guidance for clinicians for the use of FC in the detection and management of patients with IBD.

Methods: All relevant publications were analysed and practical statements were proposed based on a Delphi consensus approach.

Results: Different commercial assays have been developed but international standardisation is lacking. FC can help in the diagnosis process of IBD. In IBD, FC can predict response to therapy, detect subclinical inflammation and help to drive treatment decisions to achieve better endoscopic and clinical outcomes. After Crohn's surgery FC can identify patients with early endoscopic recurrence.

Conclusion: Although major therapeutic changes should not be based on FC alone, FC is a valuable tool to optimise the care for IBD patients.

Citing Articles

Assessing anorectal function in patients with recurrent ulcerative colitis.

Wu Q, Li T, Deng F, Yao X, Chen X, Jiang Q Int J Colorectal Dis. 2024; 39(1):110.

PMID: 39009899 PMC: 11249410. DOI: 10.1007/s00384-024-04680-1.

Optimal Use of Serum Leucine-Rich Alpha-2 Glycoprotein as a Biomarker for Small Bowel Lesions of Crohn's Disease.

Asonuma K, Kobayashi T, Kikkawa N, Nakano M, Sagami S, Morikubo H Inflamm Intest Dis. 2023; 8(1):13-22.

PMID: 37404381 PMC: 10315012. DOI: 10.1159/000530825.

A Point-of-Care Faecal Test Combining Four Biomarkers Allows Avoidance of Normal Colonoscopies and Prioritizes Symptomatic Patients with a High Risk of Colorectal Cancer.

Hijos-Mallada G, Saura N, Lue A, Velamazan R, Nieto R, Navarro M Cancers (Basel). 2023; 15(3).

PMID: 36765678 PMC: 9913693. DOI: 10.3390/cancers15030721.

The value of fecal calprotectin in infection: A systematic review.

Wen B, Te L, Liu X, Zhao J Front Physiol. 2022; 13:881816.

PMID: 35991191 PMC: 9382106. DOI: 10.3389/fphys.2022.881816.

Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn's disease in clinical remission: a pilot study.

Lee S, Hwang S, Park S, Yang D, Byeon J, Myung S Intest Res. 2022; 20(2):203-212.

PMID: 35508954 PMC: 9081997. DOI: 10.5217/ir.2021.00020.

References

Regueiro M, Strong S, Ferrari L, Fichera A . Postoperative Medical Management of Crohn's Disease: Prevention and Surveillance Strategies. J Gastrointest Surg. 2016; 20(8):1415-20. DOI: 10.1007/s11605-016-3172-5. View

Mooiweer E, Severs M, Schipper M, Fidder H, Siersema P, Laheij R . Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2014; 9(1):50-5. DOI: 10.1093/ecco-jcc/jju003. View

Roseth A, Fagerhol M, Aadland E, Schjonsby H . Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992; 27(9):793-8. DOI: 10.3109/00365529209011186. View

Yamamoto T, Shiraki M, Bamba T, Umegae S, Matsumoto K . Faecal calprotectin and lactoferrin as markers for monitoring disease activity and predicting clinical recurrence in patients with Crohn's disease after ileocolonic resection: A prospective pilot study. United European Gastroenterol J. 2014; 1(5):368-74. PMC: 4040769. DOI: 10.1177/2050640613501818. View

Colombel J, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanasek T . Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017; 390(10114):2779-2789. DOI: 10.1016/S0140-6736(17)32641-7. View

Heida A, Knol M, Kobold A, Bootsman J, Dijkstra G, van Rheenen P . Agreement Between Home-Based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity. Clin Gastroenterol Hepatol. 2017; 15(11):1742-1749.e2. DOI: 10.1016/j.cgh.2017.06.007. View

Peyrin-Biroulet L, Sandborn W, Sands B, Reinisch W, Bemelman W, Bryant R . Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015; 110(9):1324-38. DOI: 10.1038/ajg.2015.233. View

Molander P, Farkkila M, Ristimaki A, Salminen K, Kemppainen H, Blomster T . Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?. J Crohns Colitis. 2014; 9(1):33-40. DOI: 10.1016/j.crohns.2014.06.012. View

Cosnes J, Gower-Rousseau C, Seksik P, Cortot A . Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011; 140(6):1785-94. DOI: 10.1053/j.gastro.2011.01.055. View

10.

Amcoff K, Stridsberg M, Lampinen M, Magnuson A, Carlson M, Halfvarson J . Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time. Scand J Gastroenterol. 2016; 52(3):344-350. DOI: 10.1080/00365521.2016.1256424. View

11.

Menees S, Powell C, Kurlander J, Goel A, Chey W . A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015; 110(3):444-54. DOI: 10.1038/ajg.2015.6. View

12.

Sipponen T, Savilahti E, Kolho K, Nuutinen H, Turunen U, Farkkila M . Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis. 2007; 14(1):40-6. DOI: 10.1002/ibd.20312. View

13.

Schoepfer A, Beglinger C, Straumann A, Trummler M, Vavricka S, Bruegger L . Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2009; 105(1):162-9. DOI: 10.1038/ajg.2009.545. View

14.

Lewis J . The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011; 140(6):1817-1826.e2. PMC: 3749298. DOI: 10.1053/j.gastro.2010.11.058. View

15.

Mosli M, Zou G, Garg S, Feagan S, MacDonald J, Chande N . C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015; 110(6):802-19. DOI: 10.1038/ajg.2015.120. View

16.

Naismith G, Smith L, Barry S, Munro J, Laird S, Rankin K . A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease. Aliment Pharmacol Ther. 2013; 37(6):613-21. DOI: 10.1111/apt.12221. View

17.

De Vos M, Dewit O, DHaens G, Baert F, Fontaine F, Vermeire S . Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis. 2012; 6(5):557-62. DOI: 10.1016/j.crohns.2011.11.002. View

18.

Lasson A, Stotzer P, Ohman L, Isaksson S, Sapnara M, Strid H . The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2014; 9(1):26-32. DOI: 10.1016/j.crohns.2014.06.002. View

19.

Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M . Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. J Crohns Colitis. 2017; 11(6):649-670. DOI: 10.1093/ecco-jcc/jjx008. View

20.

Elkjaer M, Burisch J, Voxen Hansen V, Deibjerg Kristensen B, Slott Jensen J, Munkholm P . A new rapid home test for faecal calprotectin in ulcerative colitis. Aliment Pharmacol Ther. 2009; 31(2):323-30. DOI: 10.1111/j.1365-2036.2009.04164.x. View